AstraZeneca Taps Kinaxo to Conduct Mass Spec PTM Studies for Oncology Drug Development
January 07, 2011
AstraZeneca Taps Kinaxo to Conduct Mass Spec PTM Studies for Oncology Drug Development
The agreement calls for Kinaxo to provide quantitative analyses of PTMs on a proteome-wide scale with the expectation that "such comprehensive analysis will gain valuable insights into cellular functions of potential drug targets," the company said in a statement.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Evotec to Use PhosphoScout Platform in Oncology Biomarker Alliance with Roche
July 1, 2011 / ProteoMonitor - Kinaxo, Takeda Ink Second Collaboration for Phosphoproteomics Research
March 18, 2011 / ProteoMonitor - GSK to Buy Cellzome for $99M as Pharma Interest in Chemical Proteomics Continues to Build
May 18, 2012 / ProteoMonitor - Yale Researcher Suggests More Focus on EGFR Isoforms Needed in Development of Antibody-Based Drugs
May 20, 2011 / ProteoMonitor - UNC Team Takes Proteomic Approach to Study Drug Resistance in Triple-Negative Breast Cancer
April 20, 2012 / ProteoMonitor